Global Information
회사소개 | 문의 | 비교리스트

다형성교모세포종 치료 시장 : 세계 업계 동향, 점유율, 규모, 성장, 기회, 예측(2021-2026년)

Glioblastoma Multiforme Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

리서치사 IMARC Services Private Limited
발행일 2021년 05월 상품코드 1007154
페이지 정보 영문 배송안내 2-3일 (영업일 기준)
가격
US $ 2,299 ₩ 3,265,000 PDF (Single User License)
US $ 3,399 ₩ 4,828,000 PDF (5 User License)
US $ 4,499 ₩ 6,391,000 PDF (Corporate License)


다형성교모세포종 치료 시장 : 세계 업계 동향, 점유율, 규모, 성장, 기회, 예측(2021-2026년) Glioblastoma Multiforme Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026
발행일 : 2021년 05월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 다형성교모세포종 치료 시장은 2015-2020년간 강력한 성장을 나타냈습니다. 그레이드 IV 성상세포종이라고도 불리는 다형성교모세포종은 악성 그레이드 IV 뇌종양이며, 뇌세포내로 빠르게 확대되고, 가까운 세포로도 감염될 가능성이 있습니다. 급속한 세포 변성이 특징이기 때문에 뇌에 큰 압력이 가해지고, 격렬한 두통이나 발작을 일으킵니다. 질병의 정확한 원인은 아직 모르지만, 터코트 증후군 등 희귀한 유전성 질환을 포함한 몇 가지 요인이 그 원인이라고 생각됩니다. 이것은 뇌종양의 가장 치명적인 형태의 하나이며, 본질적으로 치료 저항성이고 환자의 진단 후 생존 기간은 매우 짧습니다. 이 질병의 현재 치료 방법에는 외과적 절제, 화학요법 및 방사선 치료 등이 있습니다. 2021-2026년간 세계의 다형성교모세포종 치료 시장 규모는 약 9%의 CAGR로 확대될 것으로 예상됩니다.

종양성 질환 유병률 증가와 세계의 노령 인구 증가는 시장 성장을 추진하는 주요 요인의 하나가 되고 있습니다. 또한 신경교종 줄기세포의 저항성에 대항하는 첨단 치료의 개발도 시장 성장에 플러스 영향을 미치고 있습니다. 또한 암 및 관련 질환의 분자 바이오테크놀러지 및 유전자 치료의 연구개발(R&D) 활동 증가에 의해 다양한 생물학적 제제의 개발이 촉진되고 있습니다. 이러한 약은 기존 치료법의 부작용을 경감하는데 도움이 되고, 환자 사이에서 더 널리 수용되게 됩니다. 또한 헬스케어 인프라를 개선하기 위해서 일부 정부에 의해 행해진 이니셔티브는 다양한 치료법의 이용 가능성에 대한 인식 확산과 함께 시장에 긍정적인 전망을 창출할 것으로 전망됩니다.

세계의 다형성교모세포종(Glioblastoma Multiforme Treatment) 시장에 대해 조사했으며, 업계 동향, 시장 예측, 약 종류·투여 경로·분자 종류·유통 채널·지역별 시장 분석, 경쟁 상황, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 서문

제2장 범위와 조사 방법

제3장 주요 요약

제4장 서론

제5장 세계의 다형성교모세포종 치료 시장

  • 시장 개요
  • 시장 실적
  • COVID-19의 영향
  • 약 종류별 시장 세분화
  • 분자 종류별 시장 세분화
  • 투여 경로별 시장 세분화
  • 유통 채널별 시장 세분화
  • 지역별 시장 세분화

제6장 약 종류별 시장 세분화

  • Temozolomide
  • Bevacizumab
  • Carmustine
  • 방사선증감제
  • 기타

제7장 투여 경로별 시장 세분화

  • 경구
  • 비경구

제8장 분자 종류별 시장 세분화

  • 소분자
  • 생물제제

제9장 유통 채널별 시장 세분화

  • 병원
  • 약국
  • 기타

제10장 지역별 시장 세분화

  • 북미
  • 유럽
  • 아시아태평양
  • 중동 및 아프리카
  • 라틴아메리카

제11장 SWOT 분석

제12장 밸류체인 분석

제13장 Porter's Five Forces 분석

제14장 가격 분석

제15장 경쟁 상황

  • 시장 구조
  • 주요 기업
  • 주요 기업 개요
    • Sun Pharmaceutical Industries
    • Celldex Therapeutics
    • Pfizer
    • F.Hoffmann La Roche
    • Bristol-Myers Squibb
    • Teva Pharmaceuticals
    • Exelixis
    • Angiochem
    • Arbor Pharmaceuticals
KSM 21.06.28

List of Figures

  • Figure 1: Global: Glioblastoma Multiforme Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Glioblastoma Multiforme Treatment Market: Sales Value (in Billion US$), 2015 - 2020
  • Figure 3: Global: Glioblastoma Multiforme Treatment Market: Breakup by Drug Type (in %), 2020
  • Figure 4: Global: Glioblastoma Multiforme Treatment Market: Breakup by Route of Administration (in %), 2020
  • Figure 5: Global: Glioblastoma Multiforme Treatment Market: Breakup by Type of Molecule (in %), 2020
  • Figure 6: Global: Glioblastoma Multiforme Treatment Market: Breakup by Distribution Channel (in %), 2020
  • Figure 7: Global: Glioblastoma Multiforme Treatment Market: Breakup by Region (in %), 2020
  • Figure 8: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Billion US$), 2021-2026
  • Figure 9: Global: Glioblastoma Multiforme Treatment Industry: SWOT Analysis
  • Figure 10: Global: Glioblastoma Multiforme Treatment Industry: Value Chain Analysis
  • Figure 11: Global: Glioblastoma Multiforme Treatment Industry: Porter's Five Forces Analysis
  • Figure 12: Global: Glioblastoma Multiforme Treatment (Temozolomide) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 13: Global: Glioblastoma Multiforme Treatment (Temozolomide) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 14: Global: Glioblastoma Multiforme Treatment (Bevacizumab) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 15: Global: Glioblastoma Multiforme Treatment (Bevacizumab) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 16: Global: Glioblastoma Multiforme Treatment (Carmustine) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 17: Global: Glioblastoma Multiforme Treatment (Carmustine) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 18: Global: Glioblastoma Multiforme Treatment (Radiosensitizers) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 19: Global: Glioblastoma Multiforme Treatment (Radiosensitizers) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 20: Global: Glioblastoma Multiforme Treatment (Other Drug Types) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 21: Global: Glioblastoma Multiforme Treatment (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 22: Global: Glioblastoma Multiforme Treatment (Oral) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 23: Global: Glioblastoma Multiforme Treatment (Oral) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 24: Global: Glioblastoma Multiforme Treatment (Parenteral) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 25: Global: Glioblastoma Multiforme Treatment (Parenteral) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 26: Global: Glioblastoma Multiforme Treatment (Small Molecule) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 27: Global: Glioblastoma Multiforme Treatment (Small Molecule) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 28: Global: Glioblastoma Multiforme Treatment (Biologics) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 29: Global: Glioblastoma Multiforme Treatment (Biologics) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 30: Global: Glioblastoma Multiforme Treatment Market: Sales through Hospitals (in Million US$), 2015 & 2020
  • Figure 31: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales through Hospitals (in Million US$), 2021-2026
  • Figure 32: Global: Glioblastoma Multiforme Treatment Market: Sales through Pharmacies (in Million US$), 2015 & 2020
  • Figure 33: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales through Pharmacies (in Million US$), 2021-2026
  • Figure 34: Global: Glioblastoma Multiforme Treatment Market: Sales through Other Distribution Channels (in Million US$), 2015 & 2020
  • Figure 35: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales through Other Distribution Channels (in Million US$), 2021-2026
  • Figure 36: North America: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 37: North America: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 38: Europe: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 39: Europe: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 40: Asia Pacific: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 41: Asia Pacific: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 42: Middle East and Africa: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 43: Middle East and Africa: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 44: Latin America: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 45: Latin America: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2021-2026

List of Tables

  • Table 1: Global: Glioblastoma Multiforme Treatment Market: Key Industry Highlights, 2020 and 2026
  • Table 2: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Drug Type (in Million US$), 2021-2026
  • Table 3: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Route of Administration (in Million US$), 2021-2026
  • Table 4: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Type of Molecule (in Million US$), 2021-2026
  • Table 5: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Distribution Channel (in Million US$), 2021-2026
  • Table 6: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Region (in Million US$), 2021-2026
  • Table 7: Global: Glioblastoma Multiforme Treatment Market: Competitive Structure
  • Table 8: Global: Glioblastoma Multiforme Treatment Market: Key Players

The global glioblastoma multiforme treatment market exhibited strong growth during 2015-2020. Glioblastoma multiforme, also known as grade IV astrocytoma, is a malignant grade IV brain tumor that rapidly spreads within the brain cells and can also infect the nearby cells. Since it is characterized by rapid cell degeneration, it creates immense pressure on the brain resulting in severe headaches and seizures. Although the exact cause of the diseases is still unknown, several factors including rare hereditary disorders such as Turcot syndrome are believed to be its cause. It is one of the most lethal forms of brain cancer and is treatment-resistant in nature, wherein the patient has an extremely short survival period post-diagnosis. The current treatment procedure of the disease includes surgical resection, chemotherapy and radiation. Looking forward, IMARC Group expects the global glioblastoma multiforme treatment market to grow at a CAGR of around 9% during 2021-2026.

Increasing prevalence of oncological diseases and a growing geriatric population across the globe are among the key factors driving the market growth. Furthermore, the development of advanced treatment methods that counter the resistive properties of glioma stem cells is also positively influencing the market growth. Additionally, increasing research and development (R&D) activities in molecular biotechnology and gene therapy for cancer and related diseases have facilitated the development of various biological drugs. These drugs assist in diminishing the side-effects of the existing treatment methods, thus creating broader acceptance amongst patients. Moreover, initiatives undertaken by several governments across the globe to improve healthcare infrastructure, along with the rising awareness of the availability of various therapies, are further expected to create a positive outlook for the market.

IMARC Group's latest report provides a deep insight into the global glioblastoma multiforme treatment market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the glioblastoma multiforme treatment market in any manner.

Report Coverage:

  • Historical, Current and Future Market Trends

Market Breakup by Drug Type:

  • Temozolomide
  • Bevacizumab
  • Carmustine
  • Radiosensitizers
  • Others

Market Breakup by Route of Administration:

  • Oral
  • Parenteral

Market Breakup by Type of Molecule:

  • Small Molecule
  • Biologics

Market Breakup by Distribution Channel:

  • Hospitals
  • Pharmacies
  • Others

Market Breakup by Region:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

Competitive Landscape:

  • The report has also analysed the competitive landscape of the market with some of the key players being Sun Pharmaceutical Industries, Celldex Therapeutics, Pfizer, F. Hoffmann La Roche, Bristol-Myers Squibb, Teva Pharmaceuticals, Exelixis, Angiochem, Arbor Pharmaceuticals, etc.

Key Questions Answered in This Report:

  • How has the global glioblastoma multiforme treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global glioblastoma multiforme treatment industry?
  • What are the key regional markets in the global glioblastoma multiforme treatment industry?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the type of molecule?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the global glioblastoma multiforme treatment industry?
  • What are the key driving factors and challenges in the global glioblastoma multiforme treatment industry?
  • What is the structure of the global glioblastoma multiforme treatment industry and who are the key players?
  • What is the degree of competition in the global glioblastoma multiforme treatment industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Glioblastoma Multiforme Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Drug Type
  • 5.5 Market Breakup by Route of Administration
  • 5.6 Market Breakup by Type of Molecule
  • 5.7 Market Breakup by Distribution Channel
  • 5.8 Market Breakup by Region
  • 5.9 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Temozolomide
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Bevacizumab
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Carmustine
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Radiosensitizers
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Parenteral
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Type of Molecule

  • 8.1 Small Molecule
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Biologics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Europe
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Asia Pacific
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Middle East and Africa
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Latin America
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Sun Pharmaceutical Industries
    • 15.3.2 Celldex Therapeutics
    • 15.3.3 Pfizer
    • 15.3.4 F.Hoffmann La Roche
    • 15.3.5 Bristol-Myers Squibb
    • 15.3.6 Teva Pharmaceuticals
    • 15.3.7 Exelixis
    • 15.3.8 Angiochem
    • 15.3.9 Arbor Pharmaceuticals
Back to Top
전화 문의
F A Q